Effects of Phosphate Binders in Moderate CKD

• Published in: Journal of the American Society of Nephrology Vol. 23; no. 8; pp. 1407 - 1415
• Main Authors: Block, Geoffrey A., Wheeler, David C., Persky, Martha S., Kestenbaum, Bryan, Ketteler, Markus, Spiegel, David M., Allison, Matthew A., Asplin, John, Smits, Gerard, Hoofnagle, Andrew N., Kooienga, Laura, Thadhani, Ravi, Mannstadt, Michael, Wolf, Myles, Chertow, Glenn M.
• Format: Journal Article
• Language: English
• Published: Washington, DC American Society of Nephrology 01.08.2012
• Subjects: Acetates - therapeutic use; Aged; Aged, 80 and over; Biological and medical sciences; Bone Density - drug effects; Calcium Compounds - therapeutic use; Chelating Agents - therapeutic use; Clinical Research; Drug toxicity and drugs side effects treatment; Female; Fibroblast Growth Factors - blood; Humans; Hyperphosphatemia - etiology; Hyperphosphatemia - prevention & control; Kidneys; Lanthanum - therapeutic use; Male; Medical sciences; Middle Aged; Nephrology. Urinary tract diseases; Parathyroid Hormone - blood; Pharmacology. Drug treatments; Phosphates - blood; Phosphates - urine; Pilot Projects; Polyamines - therapeutic use; Renal Insufficiency, Chronic - complications; Sevelamer; Toxicity: cardiovascular system; Urinary system involvement in other diseases. Miscellaneous; Vascular Calcification - chemically induced; Endocrinopathy; Kidney disease; Human; Phosphates; Nephrology; Urinary system disease; Toxicity; Cardiovascular disease; Chronic kidney disease; Urology; Vascular disease; Treatment; Parathyroid diseases; Renal failure; Calcification; Chelating agent; Complication; Hyperparathyroidism

Some propose using phosphate binders in the CKD population given the association between higher levels of phosphorus and mortality, but their safety and efficacy in this population are not well understood. Here, we aimed to determine the effects of phosphate binders on parameters of mineral metaboli...